Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Gujarat Themis Biosyn Ltd. struggles in comparison to its peers in profitability and growth metrics. It shows no revenue or profitability growth, making it an underperformer in the sector. In contrast, companies like Cipla Ltd. and Dr. Reddy's Laboratories Ltd. exhibit strong financial metrics, particularly in profitability and valuation, positioning them as sector leaders.
Strong revenue growth (YoY 13.28%), high ROE (16.63%), and attractive valuation (PE 23.73).
Solid profitability with ROE (21.76%) and favorable valuation metrics (PE 15.50).
Exceptional revenue growth (YoY 18.12%) and strong ROE (23.15%) despite higher PE (55.18).